Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences Inc.

www.gilead.com

Latest From Gilead Sciences Inc.

Intercept Makes No Changes To Ocaliva NASH Study Despite PBC Safety Issues

Data monitoring safety board okays continuation of pivotal REGENERATE study in non-alcoholic steatohepatitis despite deaths of patients receiving Ocaliva for primary biliary cholangitis.

Drug Safety Liver & Hepatic

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.

Clinical Trials Liver & Hepatic

FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

FDA's warning about 19 deaths related to excessive, off-label dosing for Ocaliva in primary biliary cholangitis spurs fears doctors will curtail prescribing and, worse, that the larger upcoming NASH market opportunity may be affected.

Drug Safety Liver & Hepatic

Sanofi And NIH To Test 3-In-1 Antibody In HIV After Monkey Trial Success

Sanofi's focus on developing multi-specific therapies is being turned to HIV.

Clinical Trials Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register